FDA Approves Mounjaro to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes

Clinical Trial Results and Cardiovascular Outcomes

Among individuals diagnosed with type 2 diabetes, cardiovascular disease ranks as a leading cause of mortality. This endorsement aligns with how GLP-1 therapies and combination treatments directly function to lower this danger.

Peminda Cabandugama, MD, Cleveland Clinic and The Obesity Society

How GLP-1 and GIP Medications Affect Heart Health

Mounjaro is an injectable medication that works by mimicking the natural gut hormones GLP-1 and GIP, which help improve blood sugar levels and reduce appetite. Under the brand name Zepbound, tirzepatide is also prescribed for weight management, while Mounjaro is specifically indicated for type 2 diabetes.

Heart conditions frequently serve as a primary reason for mortality among those living with type 2 diabetes. This regulatory clearance corresponds with the inherent capability of GLP-1 drugs and related combinations to mitigate this hazard.

Peminda Cabandugama, MD, Cleveland Clinic and The Obesity SocietyClinical studies indicate that GLP-1 medications support heart health by promoting weight loss, lowering blood pressure, reducing LDL cholesterol, and decreasing triglycerides, which are a common type of fat found in the blood. Mounjaro joins a growing class of diabetes medications with specific cardiovascular indications. In January 2020, the FDA approved Ozempic (semaglutide) to reduce cardiovascular risks in adults with type 2 diabetes, and later that year, Trulicity gained authorization to reduce heart attack and stroke risks in patients with or without established cardiovascular disease. In 2024, the regulator also approved Novo Nordisk’s anti-obesity drug Wegovy to lower cardiovascular event risks in overweight or obese adults without diabetes.

Insurance Coverage and Future Access

Whether the new FDA authorization will alter insurance coverage policies for patients remains uncertain. According to Dr. Tan, the expanded indication may improve or broaden insurance coverage terms, but because GLP-1 receptor agonists remain costly, coverage decisions ultimately depend on individual insurance plans.

For patients suffering from type 2 diabetes, cardiovascular issues represent a predominant fatal outcome. This green light mirrors the capacity of GLP-1 treatments alongside their combination regimens to actively suppress such threats.

Peminda Cabandugama, MD, Cleveland Clinic and The Obesity SocietyRecent surveys from benefits consultants indicate that while insurers are generally more likely to cover GLP-1 drugs when prescribed for type 2 diabetes, sleep apnea, or cardiovascular risk reduction, some major employers have begun scaling back coverage specifically for weight-loss indications. Medicare has initiated coverage for older adults under bridge programs, but broader market access continues to shift as drugmakers study the medications for a wider range of metabolic conditions.